For children younger than 18 years, 4 months of rifampin to treat latent Mycobacterium tuberculosis had similar rates of safety and efficacy and higher rates of adherence compared with 9 months of isoniazid, according to data published in the New England Journal of Medicine.

A multicenter, open-label (ClinicalTrials.gov identifier: NCT00170209) randomized trial assigned participants with latent M tuberculosis infection to receive either 4 months of rifampin or 9 months of isoniazid. A total of 829 randomized participants were included in the intent-to-treat analysis. In the rifampin group (n=422), 85.3% of participants completed the therapy protocol compared with 76.4% of the isoniazid group; the adjusted difference in the rates of treatment completion was 13.4 percentage points (95% CI, 7.5-19.3). 

No significant differences in rates of adverse events were reported, and less than a combined 5% of participants across both groups experienced grade 1 or 2 adverse events that were deemed to be possibly related to the drug trial. Active tuberculosis was diagnosed in 2 individuals in the isoniazid group during the 542 person-years of follow-up, including 1 case of isoniazid resistance compared with 0 cases in rifampin group during a 562 person-year follow-up (rate difference, −0.37 cases per 100 person-years; 95% CI, −0.88 to 0.14).

The trial benefited from the randomized design and complete follow-up on 98% of participants. The main limitation was the open-label design, which can introduce biases in ascertainment of completion or adverse events. However, measures to reduce these biases, such as the implementation of blinded, independent third-party adjudication of all adverse events and active cases. According to investigators, for participants with latent tuberculosis, the 4-month rifampin therapy option has better completion rates than isoniazid while having similar safety and efficacy profiles. “Rifampin has the advantage of being a single-drug regimen with existing palatable formulations for children.”


Continue Reading

Related Articles

Reference

Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379:454-463.